Asta Baranauskaite
Kaunas, KU, Lithuania
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
The utility of miR-16, miR-146a and miR-155 in serum and urine for juvenile idiopathic arthritis diagnostics and monitoring.
Journal: Pediatric rheumatology online journal
Published: May 07, 2025
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study.
Journal: Arthritis research & therapy
Published: July 09, 2024
Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial.
Journal: Therapeutic advances in musculoskeletal disease
Published: July 07, 2021
Nurse's Role from Medical Students' Perspective during Their Interprofessional Clinical Practice: Evidence from Lithuania.
Journal: Healthcare (Basel, Switzerland)
Published: June 28, 2021
Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients.
Journal: Drugs in context
Published: July 22, 2020
The impact of anti-cyclic citrullinated peptide antibody status on the management of patients with early rheumatoid arthritis: observational study results from Lithuania.
Journal: Acta medica Lituanic
Published: September 14, 2018
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 10, 2017
An optimal ultrasonographic diagnostic test for early gout: A prospective controlled study.
Journal: The Journal of international medical research
Published: June 16, 2017
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.
Journal: Annals of the rheumatic diseases
Published: May 05, 2017
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: May 04, 2017
Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results.
Journal: Rheumatology (Oxford, England)
Published: December 13, 2016
Last Updated: 09/26/2026